Docetaxel in the treatment of advanced breast cancer

Zi Ping Wang, Yan Sun, Xiang Ru Zhang, Mao Hong Zhang, Xiu Wen Wang, Xue Jun Yu, Ke Jun Nan, En Xiao Li, Ji Wei Liu, Ya Jie Gao, Xiao Qian Guan, Shu Ping Song, Li Jun Sheng, Dong Lin Wang, Zhi Xin Wang

Research output: Contribution to journalArticlepeer-review


OBJECTIVE: To evaluate the efficacy, toxicity and safety of an new domestic docetaxel in the treatment of pretreated advanced breast cancer. METHODS: Fourty-four breast cancer patients who had failed in first-line chemotherapy were included in this trial. They received docetaxel as the second-line chemotherapy. Docetaxel was administered alone at a dose of 70 mg/m2 every 3 weeks. The use of granulocyte colony-stimulating factor to prevent granulocytopenia was not permitted. The response rate and toxicity were evaluated by World Health Organization toxicity scale and performance status by Karnofsky scale. RESULTS: Of the 41 evaluable patients, 4 achieved complete response and 14 partial remission, with a response rate and clinical benefit rate of 43.9% and 85.4%, respectively. Grade 3 or grade 4 neutropenia developed in 42.9%, alopecia in 7.1% and vomiting in 4.8% of these patients. Fluid retention was not observed in this series. CONCLUSION: Three-week administration of docetaxel alone at a dose of 70 mg/m2 is effective and tolerable. It provides an alternative for the pretreated advanced breast cancer patients.

Original languageEnglish
Pages (from-to)468-470
Number of pages3
JournalZhonghua zhong liu za zhi [Chinese journal of oncology]
Issue number6
StatePublished - Jun 2006


Dive into the research topics of 'Docetaxel in the treatment of advanced breast cancer'. Together they form a unique fingerprint.

Cite this